Insulin

Betagenon co-founder publishes that AMPK activator O304 prevents gene expression changes and remobilisation of histone marks in islets of diet-induced obese mice

Retrieved on: 
Thursday, December 23, 2021
Lists of diseases, Patient, Insulin, Cell, Nature, Kidney disease, Diabetes, Ageing, Insulin resistance, AMPK, Scientific Reports, Population, Gene expression, Chromatin, Obesity, Molecular medicine, Animal, Heart failure, Pharmaceutical industry

Treatment with O304 prevented genome-wide gene expression changes associated with high fat diet and remodelled active and repressive chromatin markers in beta cells, the cells responsible for producing the body's insulin.

Key Points: 
  • Treatment with O304 prevented genome-wide gene expression changes associated with high fat diet and remodelled active and repressive chromatin markers in beta cells, the cells responsible for producing the body's insulin.
  • Glucose control was restored in the animals and markers of stress were reduced and markers of function increased in the beta cells.
  • The data are published in Scientific Reports, a member of the Nature family of journals.
  • Betagenon isa clinical stage company that develops its proprietary AMPK activators as therapies for diseases and conditions associated with the global epidemic in metabolic disorders and an aging population.

Betagenon co-founder publishes that AMPK activator O304 prevents gene expression changes and remobilisation of histone marks in islets of diet-induced obese mice

Retrieved on: 
Thursday, December 23, 2021
Lists of diseases, Patient, Insulin, Cell, Nature, Kidney disease, Diabetes, Ageing, Insulin resistance, AMPK, Scientific Reports, Population, Gene expression, Chromatin, Obesity, Molecular medicine, Animal, Heart failure, Pharmaceutical industry

Treatment with O304 prevented genome-wide gene expression changes associated with high fat diet and remodelled active and repressive chromatin markers in beta cells, the cells responsible for producing the body's insulin.

Key Points: 
  • Treatment with O304 prevented genome-wide gene expression changes associated with high fat diet and remodelled active and repressive chromatin markers in beta cells, the cells responsible for producing the body's insulin.
  • Glucose control was restored in the animals and markers of stress were reduced and markers of function increased in the beta cells.
  • The data are published in Scientific Reports, a member of the Nature family of journals.
  • Betagenon isa clinical stage company that develops its proprietary AMPK activators as therapies for diseases and conditions associated with the global epidemic in metabolic disorders and an aging population.

Insights on the Intravenous Infusion Pumps Global Market to 2027 - by Type, Application, End User and Region - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 23, 2021
Medical Devices, Health, Institute, Conditional sentence, Patient, Approximation error, Nutrient, Insulin, Patient safety, Pump, Globe, Diabetes, Social behavior, Neuromuscular blocking agents, Growth, Ageing, Urbanization, Chronic pain, COVID-19, Travel, Population, Cancer, Prevalence, Institute of Medicine, Nepal, Application, Intravenous therapy, CAGR, Adoption, Death, Infusion pump, PADE, Medical device, Pharmaceutical industry

The "Global Intravenous Infusion Pumps Market By Type, By Application, By End User, By Regional Outlook, Industry Analysis Report and Forecast, 2021 - 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Intravenous Infusion Pumps Market By Type, By Application, By End User, By Regional Outlook, Industry Analysis Report and Forecast, 2021 - 2027" report has been added to ResearchAndMarkets.com's offering.
  • The Global Intravenous Infusion Pump Market size is expected to reach $8.2 billion by 2027, rising at a market growth of 8.5% CAGR during the forecast period.
  • There are many companies that are increasingly investing in the advancement of infusion pump technology, which is expected to open new growth opportunities for the intravenous infusion pumps market.
  • One of the key factors fueling the growth of the Intravenous infusion pumps market is the rising prevalence of various chronic diseases.

Organigram Makes Additional $2.5 Million Investment in Hyasynth Biologicals, a Leading Cannabinoid Biosynthesis Company

Retrieved on: 
Wednesday, December 22, 2021
Alternative Medicine, Health, Agriculture, Natural Resources, Research, Science, THC, TSX, Intention, U.S. Securities and Exchange Commission, Patent, Nasdaq, Technology, Timeline of cannabis laws in the United States, Patient, Cannabis Act, Cannabis, SEDAR, Insulin, News, Food, Diabetes, NASDAQ, Cannabinoid, Review, Achievement, Adult, Intellectual property, Enzyme, Fermentation, SOSV, CBD, Phrase, CBG, OGI, Company, Big Bag, Edible, Research, Security (finance), Renewable energy, Fine chemical, Drug, Laurentian, Organizational chart, Mont-Tremblant, Trailblazer, Hyasynth Biologicals Inc., Organigram Holdings Inc., HYASYNTH BIOLOGICALS INC., ORGANIGRAM HOLDINGS INC.

As an early investor in biosynthesis, Organigram Holdings Inc. (NASDAQ: OGI), (TSX: OGI), the parent company of Organigram Inc. (the Company or Organigram), a leading licensed producer of cannabis, and Hyasynth Biologicals Inc. (Hyasynth) a private biotechnology company and pioneer in the field of cannabinoid science and biosynthesis are pleased to announce that Organigram has acquired an additional $2.5 million of secured convertible debentures in Hyasynth (the Debentures).

Key Points: 
  • As an early investor in biosynthesis, Organigram Holdings Inc. (NASDAQ: OGI), (TSX: OGI), the parent company of Organigram Inc. (the Company or Organigram), a leading licensed producer of cannabis, and Hyasynth Biologicals Inc. (Hyasynth) a private biotechnology company and pioneer in the field of cannabinoid science and biosynthesis are pleased to announce that Organigram has acquired an additional $2.5 million of secured convertible debentures in Hyasynth (the Debentures).
  • Proceeds of the investment are designated to advance Hyasynths production scalability as well as investment into new cannabinoid technologies (including rare cannabinoids), business development efforts and company growth.
  • In September 2018, Organigram acquired $5.0 million of Hyasynth Debentures followed by an additional $2.5 million in October 2020.
  • Todays transaction brings Organigrams total investment in Hyasynth to $10.0 million building upon previously completed milestones and recent successes of the company in advancing technology and business development.

Serum-free Media Market to Expand at CAGR of 7% during the forecast period, finds TMR Study

Retrieved on: 
Wednesday, December 22, 2021
Knowledge, TMR, Insulin, COVID-19, Vaccine, Conditional sentence, Research, Solution, CHO, CAGR, Cell biology, Growth, A-DNA, Protein

This is expected to create revenue opportunities in the serum-free media market.

Key Points: 
  • This is expected to create revenue opportunities in the serum-free media market.
  • Moreover, the role of pharmaceutical companies to boost the production of COVID-19 vaccines is creating opportunities in the serum-free media market.
  • The optimization of serum-free media to different degrees and proportions is observed in the serum-free media market.
  • Array of applications of serum-free media, of which the production of recombinant therapeutic protein is key, spells growth of the serum-free media market
    Some of the key players operating in the non-serum media market are:

Serum-free Media Market to Expand at CAGR of 7% during the forecast period, finds TMR Study

Retrieved on: 
Wednesday, December 22, 2021
Knowledge, TMR, Insulin, COVID-19, Vaccine, Conditional sentence, Research, Solution, CHO, CAGR, Cell biology, Growth, A-DNA, Protein

ALBANY, N.Y., Dec. 22, 2021 /PRNewswire/ -- Transparency Market Research: The serum free media market is estimated to expand at a CAGR of 7% during the forecast period from 2021 to 2031. Knowledge among researchers of cell biology that addition of bovine serum or calf serum to cell cultures leads to the production of non-standardized final products favors demand for serum-free media. This is expected to create revenue opportunities in the serum-free media market.

Key Points: 
  • This is expected to create revenue opportunities in the serum-free media market.
  • Moreover, the role of pharmaceutical companies to boost the production of COVID-19 vaccines is creating opportunities in the serum-free media market.
  • The optimization of serum-free media to different degrees and proportions is observed in the serum-free media market.
  • Array of applications of serum-free media, of which the production of recombinant therapeutic protein is key, spells growth of the serum-free media market
    Some of the key players operating in the non-serum media market are:

Beta Bionics Announces Data Lock of the Insulin-Only Bionic Pancreas Pivotal Trial and Enrollment into the Screening Protocol of the Bihormonal Bionic Pancreas Pivotal Trial

Retrieved on: 
Wednesday, December 22, 2021
NDA, Pancreas, Instagram, Technology, Sale, Particle-size distribution, Randomized controlled trial, LinkedIn, Time, Insulin, ADA, Diabetes, National, Twitter, Bionics, Meal, Federal, CEO, Boston University, Glucagon, Database, Human, Enrollment, Quality of life, YouTube, Hospital, Safety, Ilet, Clinical trial, Massachusetts General Hospital, GLOBE, FDA, Standard of care, Pharmaceutical industry, Dietary supplement, CONCORD

CONCORD, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. — a clinical stage medical technology company committed to the design, development, and commercialization of the iLet® Bionic Pancreas System — today announced the completion of the randomized controlled trial for the Insulin-Only Bionic Pancreas Pivotal Trial and enrollment into the screening protocol of the Bihormonal Bionic Pancreas Pivotal Trial at Massachusetts General Hospital. The iLet Bionic Pancreas is designed to mimic the biological pancreas by autonomously calculating and dosing insulin and/or glucagon as needed based on an input signal from a continuous glucose monitor worn by a person with type 1 diabetes. Insulin dosing decisions (basal, bolus, and correction) are made autonomously by the proprietary algorithm embedded on the iLet. The intent of the technology is to achieve near-normal glycemia and lift the cognitive daily burden of diabetes management in as many people with diabetes as possible.

Key Points: 
  • The cognitive and emotional impact of diabetes can lead to data and decision-making overload for people living with diabetes.
  • Enrollment into the screening protocol of the Bihormonal Bionic Pancreas Pivotal Trial began last week at Massachusetts General Hospital.
  • Beta Bionics is a clinical stage medical technology company focused on the design, development, and commercialization of its iLet Bionic Pancreas System.
  • The iLet Bionic Pancreas is an investigational device limited by Federal (or United States) law to investigational use.

Home-Use Insulin Delivery Devices Market Research Report 2021 - Global Industry Analysis and Revenue Estimation to 2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, December 20, 2021
Diabetes, Pharmaceutical, Health, Medical Supplies, Insulin, Incidence, Awareness, Diabetes, Pancreas, COVID-19, International Diabetes Federation, CAGR, Risk, Korea Disease Control and Prevention Agency, CDC, Pharmacy, Center, Population, IDF, Patient, Growth, Hospital, Medical device, Pharmaceutical industry

The "Home-Use Insulin Delivery Devices Market Research Report: By Type, Distribution Channel - Global Industry Analysis and Revenue Estimation to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Home-Use Insulin Delivery Devices Market Research Report: By Type, Distribution Channel - Global Industry Analysis and Revenue Estimation to 2030" report has been added to ResearchAndMarkets.com's offering.
  • From $7,276.9 million in 2020, the size of the global home-use insulin delivery devices market will increase to $19,087.6 million in 2030, at a 10.2% CAGR between 2021 and 2030, according to the market research report.
  • The home-use insulin delivery devices market was relatively unharmed by the COVID-19 pandemic as most of the pharmaceutical companies were operational.
  • The highest home-use insulin delivery devices market CAGR in the coming years, under the type segment, will be witnessed by insulin pens.

ALR Technologies Releases an Open Letter to Shareholders

Retrieved on: 
Monday, December 20, 2021
Method, Failure, NYSE American, Standard of care, CDC, FDA, Conditional sentence, Company, Diabetes, BGM, Diagnosis, PETS, NYSE, Feedback, Animal, Industry, Nasdaq, American Stock Exchange Building, CGMS-A, Automated insulin delivery systems, Veterinarian, Time, Insulin, Adoption, Data management, Intention, Glucose meter, Safety, Moment of inertia, Artificial intelligence, Veterinary medicine, Self-management, Patent, Letter, Program, CGM, Blood, Maintenance, Infection, Partnership, Health, Human, HIPAA, Pharmaceutical industry, Medical device, Security (finance)

But while we believe we have the best-in-class platform, it is utilizing a Blood Glucose Meter (BGM) to collect data.

Key Points: 
  • But while we believe we have the best-in-class platform, it is utilizing a Blood Glucose Meter (BGM) to collect data.
  • We believe that throughout 2022 the market will recognize the value of ALRT as we continue to deliver on the items discussed in this letter and in previous press releases.
  • Ltd. is a wholly owned subsidiary of ALR Technologies Inc. On June 1, 2021, ALR Technologies Inc. announced its intention to migrate to Singapore.
  • More information about ALR Technologies Inc. can be found at www.alrt.com.

LANNETT ANNOUNCES SUBMISSION OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR BIOSIMILAR INSULIN GLARGINE

Retrieved on: 
Monday, December 20, 2021
Investigational New Drug, HEC, Food, BLA, FDA, LCI, Company, NYSE, IND, Insulin, Risk, SEC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, PD, Biologics license application, Diabetes, SAHPRA, News, Pharmaceutical industry, Insulin glargine

PHILADELPHIA, Dec. 20, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced the submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the pivotal clinical trial of biosimilar insulin glargine, a product the company is co-developing with its strategic alliance partners within the HEC Group of companies (HEC).

Key Points: 
  • PHILADELPHIA, Dec. 20, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced the submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the pivotal clinical trial of biosimilar insulin glargine, a product the company is co-developing with its strategic alliance partners within the HEC Group of companies (HEC).
  • If successful, we would anticipate filing the Biologics License Application (BLA) in early 2023 and potentially launching the product by early 2024."
  • Submission of the IND kicks off the final regulatory process before Lannett starts the pivotal trial.
  • The trial site has experience with clinical insulin trials and has been used by other innovator firms for their insulin clinical trials.